OKMETIC'S INTERIM REPORT 1 JANUARY - 30 SEPTEMBER 2014: STRONG THIRD QUARTER DUE TO SOLID DEMAND FOR SENSOR WAFERS



OKMETIC OYJ STOCK EXCHANGE RELEASE 23 OCTOBER 2014 AT 8.00 A.M.

INTERIM REPORT 1 JANUARY - 30 SEPTEMBER 2014: STRONG THIRD QUARTER DUE TO SOLID
DEMAND FOR SENSOR WAFERS

Unless otherwise stated, figures in parenthesis refer to the corresponding
period in the previous year.

JULY-SEPTEMBER IN BRIEF:

 - Net sales amounted to 19.3 (18.2) million euro, up 5.9%.
 - Silicon wafer shipments amounted to 17.5 (17.8) million euro, down 1.3%.
 - Operating profit was 2.8 (1.4) million euro, corresponding to 14.3% (7.8%) of
net sales.
 - Profit for the period was 2.2 (0.8) million euro.
 - Basic earnings per share was 0.13 (0.05) euro.
 - Net cash flow from operations amounted to 3.6 (3.5) million euro.

JANUARY-SEPTEMBER IN BRIEF:

 - Net sales amounted to 55.4 (51.7) million euro, up 7.2%.
 - Silicon wafer shipments amounted to 52.9 (50.2) million euro, up 5.4%.
 - Operating profit was 4.8 (4.8) million euro, corresponding to 8.7% (9.2%) of
net sales.
 - Profit for the period was 3.7 (3.4) million euro.
 - Basic earnings per share was 0.22 (0.20) euro.
 - Net cash flow from operations amounted to 6.2 (4.8) million euro.

SHORT-TERM OUTLOOK

The demand for semiconductors is expected to grow in 2014. Also for the silicon
wafer market, growth is expected in 2014. Following the growth in shipment
volumes, the long decline in the value of the silicon wafer market is
anticipated to end this year.

The demand for Okmetic's demanding sensor wafers is estimated to grow year-on-
year in 2014, and the price level is expected to remain fairly stable.

Prices of semiconductor wafers are being hit by the weakened Japanese yen, as
the Japanese manufacturers hold a significant stake of the silicon wafer market.
However, the demand is expected to pick up somewhat in 2014 compared to 2013.

Other business sales are not expected to materially differ from the low level of
year 2013.

In the fourth quarter, the demand for silicon wafers is expected to be lower
than in the second and third quarters of the year, in accordance with normal
seasonal fluctuation.

The company retains its existing guidance, according to which net sales and
operating profit in 2014 are estimated to exceed the level of year 2013.

PRESIDENT KAI SEIKKU:

"The strong sales trend of strategically important sensor wafers continued in
January-September, as the shipments grew by 12.3 percent from the comparison
period. The demand for sensor wafers was particularly strong in Europe. Sales
grew in all of the company's main market areas excluding Japan. Sensor wafer
development has been in line with the long-term growth target as redefined in
the Capital Markets Day at the end of September. In contrast, the demand for
semiconductor wafers has clearly been weaker in 2014 in relation to the
corresponding period last year.

The third quarter is traditionally the peak demand season for Okmetic's
products. Operating profit, 2.8 million euro, strengthened notably in July-
September both quarter-on-quarter (1.1 million euro in Q2 2014) and year-on-year
(1.4 million euro in Q3 2013). The increase in profitability was driven by the
sales of high value added products that is growing in line with Okmetic's
strategy. In the third quarter, also the strengthening of the US dollar as well
as non-operational income in the United States (0.3 million euro) improved
operating profit. Operating profit in the third quarter of last year was
burdened by non-operational items (0.6 million euro).

When assessing profitability of the business it is worth noticing that
depreciation grew by 0.7 million euro in January-September. Operating profit
before depreciation was 9.7 (9.0) million euro in January-September. Net cash
flow from operating activities, 6.2 million euro, was at a good level in
January-September considering the extra polysilicon inventory tied up in working
capital. The company's working capital is up as a result of a higher raw
material inventory, which has grown due to the polysilicon purchasing contracts.
With the growing of solar crystals based on own raw material now ended, this
inventory is being released. A reduction in working capital is not expected
until the expiration of the long-term contracts at the end of 2015.

The ongoing annual contract negotiations as well as new customerships and
customer qualifications indicate a continuing positive trend in sensor wafers
for next year. Meanwhile, in semiconductor wafers, prices will remain under
pressure."

KEY FIGURES

 1,000 euro         1 Jul-  1 Jul-  1 Jan-  1 Jan- 1 Jan-
                   30 Sep, 30 Sep, 30 Sep, 30 Sep, 31 Dec
                      2014    2013    2014    2013   2013



 Net sales          19,320  18,242  55,425  51,680 68,516

 Operating profit
 before
 depreciation
 (EBITDA)            4,420   2,921   9,745   9,024 10,905

 Operating profit    2,757   1,423   4,822   4,768  5,031

  % of net sales      14.3     7.8     8.7     9.2    7.3

 Profit for
 the period          2,219     816   3,749   3,395  3,842

 Basic earnings
 per share,
 euro                 0.13    0.05    0.22    0.20   0.23

 Net cash flow
 from operating
 activities          3,644   3,481   6,209   4,811  9,726

 Net interest-
 bearing
 liabilities         4,174   6,196   4,174   6,196  6,530

 Equity ratio, %      70.6    70.5    70.6    70.5   68.2

 Average number
 of personnel
 during the period     379     369     371     366    363


MARKETS

Customer industries sensor and semiconductor industry

Sensor industry

The increasing use of micro sensors in many consumer electronics and automotive
industry products has accelerated sensor sales growth. In 2014, the sale value
of sensor industry is estimated to grow by 6-11 percent. In terms of volume,
sensor shipments are likely to clearly reach a new record in 2014, too. (IHS,
Yole)

Semiconductor industry

In the third quarter of 2014, the sales of the global semiconductor industry in
US dollars continued to grow. In January to August, the sales grew by 10 percent
from the corresponding period last year (SIA). For the whole year 2014, the
growth estimates have settled between 6.5 and 9.8 percent (WSTS, Gartner,
Cowan). Almost all product areas contributed to continued semiconductor sales
growth, especially tablet computers (SIA, Gartner).

Silicon wafer market

According to the report of SMG, the group of silicon wafer suppliers in SEMI (a
global umbrella organisation for semiconductor materials and equipment
industry), the surface area of silicon wafer shipments calculated in square
inches grew by 10 percent year-on-year in the first half of 2014. For the whole
year 2014, SEMI forecasts 7 percent growth, which would break the record in the
yearly volume of silicon wafer shipments. Following the growth in shipment
volumes, the long decline in the value of the silicon wafer market in US dollars
is expected to end this year.

The key customer areas for Okmetic in the silicon wafer market

In line with its strategy, Okmetic seeks niches in the silicon wafer market,
where growth exceeds market average and in which the company has special
expertise. Okmetic supplies primarily 150mm and 200mm wafers. The sensor/MEMS
industry is a key growth area for Okmetic. MEMS market grows as portable
consumer products, automotive electronics, and industrial process control
increase.

In the semiconductor market, Okmetic's growth areas include discrete and power
semiconductors. In these wafer markets, areas for growth include, among others,
components used in the production of renewable energy, increasing automotive
electronics, portable consumer products, as well as different solutions related
to power supply and efficiency improvement.

SALES

In the third quarter, net sales grew by 5.9 percent year-on-year and amounted to
19.3 (18.2) million euro. In January-September, net sales grew by 7.2 percent
from the comparison period and amounted to 55.4 (51.7) million euro. Sensor
wafer shipments increased whereas semiconductor wafer shipments diminished from
last year in both periods. There have been no significant changes in the market
positions of Okmetic in the product groups important to the company.

Sales per customer area


                 1 Jul-  1 Jul-  1 Jan-  1 Jan-  1 Jan-
                30 Sep, 30 Sep, 30 Sep, 30 Sep, 31 Dec,
                   2014    2013    2014    2013    2013



 Sensor wafers      61%     59%     63%     59%     59%

 Semiconductor
 wafers             34%     38%     34%     38%     37%

 Other business      5%      3%      3%      3%      4%



The value of sensor wafer shipments grew by 12.3 percent year-on-year in
January-September. In the same period, the value of semiconductor wafer
shipments declined by 5.3 percent. In the third quarter, semiconductor wafer
shipments were, however, bigger than in the first and second quarters.
The value of Other business shipments amounted to 1.9 (1.7) million euro in
January-September.

Sales per market area

                1 Jul-  1 Jul-  1 Jan-  1 Jan-  1 Jan-
               30 Sep, 30 Sep, 30 Sep, 30 Sep, 31 Dec,
                  2014    2013    2014    2013    2013



 North America     37%     43%     38%     41%     42%

 Europe            42%     41%     41%     40%     40%

 Asia              21%     16%     21%     19%     18%


Regionally, most sales originated in Europe and North America.

PROFITABILITY

July-September

Okmetic's operating profit amounted to 2.8 (1.4) million euro, i.e. 14.3 (7.8)
percent of net sales in July-September.

The operating profit was favourably impacted by the strengthening of the US
dollar, the sale of a redundant lot at the Allen production site, 0.2 million
euro, as well as insurance claims paid out to the Allen plant, 0.1 million euro.
In the comparison period, operating profit was reduced by non-operational items
(0.6 million euro).

Profit for the period amounted to 2.2 (0.8) million euro. Basic earnings per
share was 0.13 (0.05) euro. Diluted earnings per share was 0.13 (0.05) euro.

January-September

In January-September, Okmetic's operating profit amounted to 4.8 (4.8) million
euro, i.e. 8.7 (9.2) percent of net sales. Profit for the period amounted to
3.7 (3.4) million euro. Basic earnings per share was 0.22 (0.20) euro. Diluted
earnings per share was 0.22 (0.20) euro.

FINANCING

The company's financial position is solid. In January-September, net cash flow
from operations amounted to 6.2 (4.8) million euro. The changes in working
capital tied up in operations weakened cash flow from operations by 2.7 (5.0)
million euro.

On 30 September 2014, the company's interest-bearing liabilities amounted to
14.5 (11.8) million euro. Okmetic issued a multi-issuer bond in June, due to
which interest-bearing liabilities increased by five million euro. The maturity
of the multi-issuer bond is five years. The financing is used for investments
and general corporate purposes.

At the end of the reporting period, cash and cash equivalents amounted to 10.3
(5.6) million euro. On 30 September 2014, the company's net debt was 4.2 million
euro (on 30 September 2013, net debt amounted to 6.2 million euro).

The group has ensured liquidity with committed credit facilities of 6.0 million
euro. On 30 September 2014, the committed credit facilities were fully unused
(as well as on 30 September 2013).

Return on equity amounted to 8.4 (7.4) percent. The company's equity ratio was
70.6 (70.5) percent. Equity per share was 3.69 (3.67) euro.

INVESTMENTS

In January-September, Okmetic's capital expenditure amounted to 2.5 (5.8)
million euro. The investments were mainly for increasing capacity of 200mm
wafers at the Vantaa plant.

PRODUCT DEVELOPMENT

The company expensed 1.8 (1.9) million euro in product development projects in
January-September, corresponding to 3.2 (3.6) percent of net sales. Product
development costs have not been capitalised. Emphasis in product development was
on engineered products. Focus areas include broadening the SOI product family,
improving capability in 200mm wafers as well as developing crystal growing to
enhance capability in high and low resistivity products.

PERSONNEL

On average, Okmetic employed 371 (366) people in January-September. At the end
of the period, Okmetic had 363 (356) employees, of which 318 worked in Finland,
39 in the US, five in Japan, and one in Hong Kong.

BUSINESS RISKS

There have been no significant changes in the company's near future business
risks and uncertainties.

Okmetic's business is confronted by risks, which may arise from the company's
operations or changes in its operating environment. Risks that, if materialized,
can have an adverse effect on the company's operations and valuation are
described below.

Okmetic's silicon wafer sales are targeted at the sensor and semiconductor
producers in the electronics industry. The demand for semiconductor wafers is
sensitive to economic fluctuations, and changes in the market situation can be
sudden and dramatic. The demand for sensor wafers is more stable. The
proliferation of sensors in consumer electronics applications may, however,
increase the susceptibility of this market too to economic fluctuations.

Okmetic has existing polysilicon purchasing obligations partly until the end of
2015. Since the price level of the solar cell market has dropped, the validity
of long-term polysilicon purchase contracts typical of the industry may cause a
price risk.

Okmetic's share of the global silicon wafer market is around one percent, and
the market prices have a notable effect on the price development of Okmetic's
products. The company has considerable pricing power only in its own special
products. The pricing of other wafers is largely based on global market price.

Okmetic operates globally, and therefore the company's business is affected by
risks due to exchange rate fluctuations, consisting of cash flows from purchases
and sales. A significant part of sales is conducted in US dollars. Despite
hedging, the company remains exposed to exchange rate fluctuations.

Substantial amounts of electricity are used in Okmetic's production. Despite
hedging, the company is exposed to fluctuations in the price of electricity.

SHARES AND SHAREHOLDERS

On 30 September 2014, Okmetic Oyj's paid-up share capital, as entered in the
Finnish Trade Register, was 11,821,250 euro. The number of shares was
17,287,500. The shares have no nominal value attached. Each share entitles to
one vote at general meetings. The company has one class of shares. The company's
shares are included in the Finnish book-entry system.

Major shareholders on
30 September 2014
                             Shares, Share,
                                 pcs      %


 Ilmarinen Mutual Pension
 Insurance Company         1,004,985    5.8

 Oy Ingman Finance Ab        870,000    5.0

 Mandatum Life Insurance
 Company Limited             800,000    4.6

 The State Pension Fund      600,000    3.5

 Nordea Nordic Small
 Cap Fund                    528,810    3.1

 Varma Mutual Pension
 Insurance Company           477,175    2.8

 Okmetic Oyj *)              416,763    2.4

 Etra-Invest Oy Ab           400,000    2.3

 Investment Fund
 Taaleritehdas Arvo
 Markka Osake                300,100    1.7

 Nordea Finland Small Cap
 Fund                        250,095    1.5

 Foreign investors and
 nominee accounts held by
 custodian banks           2,876,684   16.6

 Other                     8,762,888   50.7

 Total                    17,287,500  100.0



*)Of Okmetic Oyj's shares, 400,000 pcs are owned through Okmetic Management Oy.

SHARE PRICE PERFORMANCE AND TRADING

A total of 2.8 (2.2) million shares were traded between 1 January and 30
September 2014, representing 16.1 (12.9) percent of the weighted average of
share total of 17.3 (17.3) million during the period. The lowest quotation
during the period was 4.38 (4.25) euro, and the highest 5.25 (5.55) euro, with
the average trading price being 4.67 (4.78) euro. The closing quotation for the
period was 4.95 (5.31) euro. At the end of the period, the market capitalisation
amounted to 85.6 (91.8) million euro.

OWN SHARES AND DIRECTED SHARE ISSUES

In a directed share issue on 16 January 2014, Okmetic Oyj transferred a total of
150,000 own shares held by the company to President Kai Seikku (140,000 shares)
and Deputy to the President of that time, Mikko Montonen (10,000 shares).
Subscription price per share was determined using the average trading price of
the company's share weighted by trading volume in NASDAQ OMX Helsinki Oy on 16
January 2014, and was 4.9969 euro.

On 13 February 2014, Okmetic Oyj's board of directors announced of its decision
to transfer a total of 11,919 own shares held by the company as a part of the
company's share-based incentive scheme for the executive management group, of
which the company gave a stock exchange release on 12 February 2013.

According to the decision of the annual general meeting, Okmetic Oyj transferred
a total of 15,441 shares to the board members as payment of the annual
remuneration on 9 May 2014.

At the end of the reporting period Okmetic held 416 763 (194 123) own shares, of
which 400 000 shares through Okmetic Management Oy. The number of own shares
corresponds to approximately 2.4 (1.1) percent of all Okmetic shares and votes.

OTHER EVENTS IN THE INTERIM PERIOD

On 15 January 2014, the board of directors decided to dissolve the ownership
arrangement of Okmetic Management Oy, owned by President Kai Seikku and Deputy
to the President of that time, Mikko Montonen, with an arrangement in which
Okmetic Oyj acquired the entire share capital of Okmetic Management Oy. Also
400,000 shares of Okmetic Oyj were transferred to the group via Okmetic
Management Oy, as well as a loan receivable of Okmetic Oyj from Okmetic
Management Oy. The value of the arrangement for the part of shares owned by
Okmetic Management Oy was determined using the average trading price weighted by
trading volume of the company's share in NASDAQ OMX Helsinki Oy on 16 January
2014, 4.9969 euro. There were no shareholders of Okmetic Management Oy in the
board of directors of Okmetic Oyj.

Mikko Montonen, Executive Vice President, Customers and Markets, Deputy to the
President, resigned from Okmetic on 26 February 2014 to assume a new position
with another company. Mr. Montonen's management responsibilities at Okmetic
ended on 6 April 2014.

Anna-Riikka Vuorikari-Antikainen, then Senior Vice President, Products, was
appointed Senior Vice President, Customers and Markets from 7 April 2014. Ms.
Vuorikari-Antikainen is also responsible for customer support.
Atte Haapalinna, then Senior Vice President, Customer Support, was appointed
Senior Vice President, Products from 7 April 2014.

In connection with Okmetic's Capital Markets Day on 26 September 2014, the
company modified its long-term targets slightly as:
- Organic growth of sensor wafer business at 10 percent per annum or more
- Operating profit to account for 10 percent of net sales or more

This implies no explicit growth target for sales of other type of wafers, or
Other business.

CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 30 SEPTEMBER 2014
(unaudited)


ACCOUNTING POLICIES

These interim financial statements have been prepared in accordance with IAS
34, Interim Financial Reporting.

In preparing these interim financial statements, Okmetic has followed the same
accounting policies as in the financial statements for 2013 except for the
effect of changes required by the adoption of certain new or revised standards
and interpretations as of 1 January 2014, which have been described in financial
statements 2013. The adoption of the new and revised standards and
interpretations has not had an effect on the figures presented from the
reporting period.


CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 1,000 euro      1 Jul-  1 Jul-  1 Jan-  1 Jan-  1 Jan-
                30 Sep, 30 Sep, 30 Sep, 30 Sep, 31 Dec,
                   2014    2013    2014    2013    2013



 Net sales       19,320  18,242  55,425  51,680  68,516

 Cost of sales  -14,942 -14,594 -44,098 -40,536 -54,918

 Gross profit     4,378   3,648  11,327  11,144  13,598

 Other income
 and expenses    -1,621  -2,225  -6,505  -6,376  -8,567

 Operating
 profit           2,757   1,423   4,822   4,768   5,031

 Financial
 income and
 expenses            49    -143     -28    -399    -630

 Profit before
 tax              2,806   1,280   4,794   4,369   4,401

 Income tax        -587    -464  -1,045    -974    -559

 Profit for
 the period       2,219     816   3,749   3,395   3,842



 Other
 comprehensive
 income:

 Items that may
 be
 reclassified
 to profit or
 loss in
 subsequent
 periods

 Cash flow
 hedges              16     100      17     -17     -58

 Translation
 differences        557    -323     566     -27     -60

 Other
 comprehensive
 income for the
 period, net of
 tax                573    -224     584     -44    -118



 Total
 comprehensive
 income for the
 period           2,792     591   4,333   3,351   3,724



 Profit for the
 period
 attributable
 to:

 Equity holders
 of the parent
 company          2,219     816   3,749   3,395   3,842



 Total
 comprehensive
 income
 attributable
 to:

 Equity holders
 of the parent
 company          2,792     591   4,333   3,351   3,724



 Basic earnings
 per share,
 euro              0.13    0.05    0.22    0.20    0.23

 Diluted
 earnings per
 share, euro       0.13    0.05    0.22    0.20    0.22




CONDENSED CONSOLIDATED BALANCE SHEET

 1,000 euro             30 Sep, 30 Sep, 31 Dec,
                           2014    2013    2013



 Assets

 Non-current assets

 Property, plant and
 equipment               42,864  45,038  45,295

 Intangible assets          740     888     897

 Other receivables          732   2,020   1,419

 Total non-current
 assets                  44,335  47,945  47,611



 Current assets

 Inventories             17,748  17,893  16,634

 Receivables             16,440  15,432  14,572

 Cash and cash
 equivalents             10,279   5,617   5,214

 Total current
 assets                  44,467  38,941  36,420



 Total assets            88,802  86,886  84,031



 Equity and liabilities

 Equity

 Equity attributable
 to equity holders of
 the parent company

 Share capital           11,821  11,821  11,821

 Other equity            50,398  49,398  45,451

 Total equity            62,219  61,219  57,273



 Liabilities

 Non-current
 liabilities             13,407  12,804  10,533

 Current liabilities     13,175  12,863  16,226

 Total liabilities       26,583  25,667  26,759



 Total equity and
 liabilities             88,802  86,886  84,031



CONDENSED CONSOLIDATED CASH FLOW STATEMENT

 1,000 euro                         1 Jan-  1 Jan-  1 Jan-
                                   30 Sep, 30 Sep, 31 Dec,
                                      2014    2013    2013



 Cash flows from operating
 activities:

 Profit before tax                   4,794   4,369   4,401

 Adjustments                         4,399   4,591   6,566

 Change in working capital          -2,697  -5,000  -2,091

 Financial items                      -357    -121    -126

 Tax paid                               70     972     976

 Net cash from
 operating activities                6,209   4,811   9,726



 Cash flows from investing
 activities:

 Purchases of property,
 plant and equipment                -3,335  -7,784  -9,089

 Proceeds from sale of
 property, plant and
 equipment                             696       -       -

 Net cash used in
 investing activities               -2,639  -7,784  -9,089



 Cash flows from financing
 activities:

 Proceeds from long-
 term borrowings                     5,000  10,000  10,000

 Proceeds of short-term borrowings
                                     4,000      24   1,024

 Payments of long-term
 borrowings                         -2,000  -1,000  -1,000

 Payments of short-term
 borrowings                         -4,024  -3,043  -4,043

 Payments of finance
 lease liabilities                    -437    -349    -478

 Other items                            36      10      10

 Dividends paid                       -578  -4,170  -6,763

 Capital repayment                       -       -  -1,169

 Share issue                           750       -       -

 Acquisition of Okmetic
 Management Oy's share
 capital                            -1,516       -       -

 Net cash used in
 financing activities                1,230   1,473  -2,419



 Increase (+) /
 decrease (-) in cash
 and cash equivalents                4,799  -1,500  -1,782

 Exchange rate changes                 266    -171    -292

 Cash and cash
 equivalents at
 the beginning
 of the period                       5,214   7,288   7,288

 Cash and cash
 equivalents at
 the end of the
 period                             10,279   5,617   5,214




CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

            Equity attributable to equity holders of parent company

              Share  Share         Reserve    Other Retained  Total
            capital pre-mium  for invested reserves earnings
                             un-restricted       1)
 1,000 euro                         equity

 Balance at
 31 Dec,
 2013        11,821   20,045             3    1,756   23,647 57,273

 Profit for
 the period                                            3,749  3,749

 Other com-
 prehensive
 income,
 net of
 tax:

 Cash flow
 hedges                                          17              17

 Trans-
 lation
 differ-
 ences                                          566             566

 Total com-
 prehensive
 income for
 the period                                     584    3,749  4,333



 Share
 issue                                 750                      750

 Share-
 based
 payments                                                221    221

 Acquisi-
 tion of
 non-
 control-
 ling
 interest                                               -357   -357

 Balance at
 30 Sep,
 2014        11,821   20,045           753    2,339   27,260 62,219



 Balance at
 31 Dec,
 2012        11,821   20,045         1,200    1,874   26,919 61,860

 Profit for
 the period                                            3,395  3,395

 Other com-
 prehensive
 income,
 net
 of tax:

 Cash flow
 hedges                                         -17             -17

 Trans-
 lation
 differ-
 ences                                          -27             -27

 Total com-
 prehensive
 income for
 the period                                     -44    3,395  3,351



 Share-
 based
 payments                                                178    178

 Dividends
 distribut-
 ed                                                   -4,170 -4,170

 Balance at
 30 Sep,
 2013        11,821   20,045         1,200    1,830   26,323 61,219


1)"Other reserves" contains hedge reserve and translation differences.

Acquisition of shares of Okmetic Management Oy is treated as acquisition of non-
controlling interest.


CHANGES IN PROPERTY, PLANT AND EQUIPMENT

 1,000 euro            1 Jan-  1 Jan-  1 Jan-
                      30 Sep, 30 Sep, 31 Dec,
                         2014    2013    2013



 Carrying amount
 at the beginning
 of the period         45,295  43,433  43,433

 Additions              2,465   5,777   7,648

 Disposals               -501      -9      -9

 Depreciation          -4,678  -4,080  -5,623

 Exchange differences     283     -83    -154

 Carrying amount
 at the end of
 the period            42,864  45,038  45,295



COMMITMENTS AND CONTINGENCIES

 1,000 euro              30 Sep, 30 Sep, 31 Dec,
                            2014    2013    2013



 Loans secured with
 collaterals               8,000  10,000  10,000

 Collaterals              17,128  17,128  17,128

 Off-balance sheet
 lease commitments           308     380     395



 Capital commitments       1,902   2,112   1,910



 Nominal values of
 derivative contracts

 Currency options, call      226       -     948

 Currency options, put         -       -     182

 Currency forward
 agreements                1,631     903   1,144

 Electricity derivatives   1,270   2,117   1,847



 Fair values of
 derivative contracts

 Currency options, call        0       -      12

 Currency options, put         -       -      -1

 Currency forward
 agreements                  -77      15      20

 Electricity derivatives    -205    -173    -350


The contract price of the derivatives has been used as the nominal value of the
underlying asset.


HIERARCHY LEVELS OF DERIVATIVE CONTRACTS MEASURED AT FAIR VALUE

 1,000 euro       30 Sep, 2014              30 Sep, 2013

             Level 1 Level 2 Level 3   Level 1 Level 2 Level 3

 Financial
 assets

 Derivative
 financial
 instruments       -      13       -         -      38       -



 Financial
 liabilities

 Derivative
 financial
 instruments       -     296       -         -     196       -


Fair value estimation

The  group's  financial  instruments  that  are  measured at fair value comprise
derivatives  used for hedging and  held for trading, and  they are classified on
hierarchy level 2.

Fair values of level 2 instruments are based on other data than quoted prices in
active markets, but on data from which the asset is observable, either directly
(i.e. price) or indirectly (i.e. derived from the prices).

Fair value determination

The fair values of currency derivatives are determined by using mark-to-market
method at the reporting date.

The fair values of electricity derivatives are determined on the basis of market
quotations and contract prices of the instruments at the reporting date.


KEY FIGURES SHOWING FINANCIAL PERFORMANCE

 1,000 euro                1 Jan-  1 Jan-  1 Jan-
                          30 Sep, 30 Sep, 31 Dec,
                             2014    2013    2013



 Net sales                 55,425  51,680  68,516

 Change in net sales
 compared to the previous
 year's period, %             7.2   -17.2   -17.5

 Export and foreign
 operations share
 of net sales, %             91.2    91.2    91.8

 Operating profit before
 depreciation (EBITDA)      9,745   9,024  10,905

   % of net sales            17.6    17.5    15.9

 Operating profit           4,822   4,768   5,031

   % of net sales             8.7     9.2     7.3

 Profit before tax          4,794   4,369   4,401

   % of net sales             8.6     8.5     6.4

 Return on equity, %          8.4     7.4     6.4

 Return on investment, %      9.1     8.6     6.7

 Non-interest-bearing
 liabilities               12,129  13,855  15,014

 Net interest-bearing
 liabilities                4,174   6,196   6,530

 Net gearing ratio, %         6.7    10.1    11.4

 Equity ratio, %             70.6    70.5    68.2

 Capital expenditure        2,465   5,777   7,648

   % of net sales             4.4    11.2    11.2

 Depreciation               4,923   4,256   5,874

 Research and development
 expenditure                1,801   1,876   2,779

   % of net sales             3.2     3.6     4.1



 Average number of
 personnel during
 the period                   371     366     363

 Personnel at the
 end of the period            363     356     355





KEY FIGURES PER SHARE

When calculating equity per share, Okmetic's own shares and Okmetic shares owned
by Okmetic Management Oy are deducted from the total number of shares.

 Euro                    30 Sep, 30 Sep, 31 Dec,
                            2014    2013    2013

 Basic earnings
 per share                  0.22    0.20    0.23

 Diluted earnings
 per share                  0.22    0.20    0.22

 Equity per share           3.69    3.67    3.43

 Capital repayment per
 share                         -       -    0.07

 Dividend per share            -       -       -

 Dividends/earnings, %         -       -       -

 Effective dividend
 yield, %                      -       -       -

 Price/earnings(P/E)           -       -    20.9



 Share performance
 (1.1.-)

 Average trading price      4.67    4.78    4.92

 Lowest trading price       4.38    4.25    4.25

 Highest trading price      5.25    5.55    5.66

 Trading price at the
 end of the period          4.95    5.31    4.82

 Market capitalisation
 at the end of the
 period, 1,000 euro       85,573  91,797  83,326



 Trading volume,
 transactions, 1,000 pcs   2,784   2,223   3,382

 In relation to weighted
 average number of
 shares, %                  16.1    12.9    19.6

 Trading volume,
 1,000 euro               13,048  10,620  16,647

 The weighted average
 number of shares during
 the period under review
 adjusted by the share
 issue, 1,000 pcs         17,288  17,288  17,288

 The number of shares at
 the end of the period
 adjusted by the share
 issue, 1,000 pcs         17,288  17,288  17,288



QUARTERLY KEY FIGURES

 1,000 euro                  10-12/   7-9/   4-6/   1-3/
                               2014   2014   2014   2014



 Net sales                          19,320 18,700 17,405

   Compared to previous
   quarter, %                          3.3    7.4    3.4

   Compared to corresponding
   period last year, %                 5.9    9.8    6.1

 Operating profit                    2,757  1,137    928

   % of net sales                     14.3    6.1    5.3

 Profit before tax                   2,806  1,096    892

   % of net sales                     14.5    5.9    5.1



 Net cash flow generated
 from:
 Operating activities                3,644  1,932    632

 Investing activities                  261 -1,263 -1,637

 Financing activities               -3,157  4,859   -472

 Increase/decrease in cash
 and cash equivalents                  748  5,528 -1,477



 Personnel at the end
 of the period                         363    393    354



 1,000 euro                  10-12/   7-9/   4-6/   1-3/
                               2013   2013   2013   2013



 Net sales                   16,837 18,242 17,035 16,403

   Compared to previous
   quarter, %                  -7.7    7.1    3.9  -20.7

   Compared to corresponding
   period last year, %        -18.6  -13.2  -24.2  -13.2

 Operating profit               263  1,423  1,971  1,373

   % of net sales               1.6    7.8   11.6    8.4

 Profit before tax               32  1,280  1,812  1,277

   % of net sales               0.2    7.0   10.6    7.8



 Net cash flow generated
 from:
 Operating activities         4,915  3,481    519    811

 Investing activities        -1,304 -1,687 -1,966 -4,131

 Financing activities        -3,892 -1,155 -7,276  9,904

 Increase/decrease in cash
 and cash equivalents          -281    639 -8,724  6,585



 Personnel at the end
 of the period                  355    356    379    354



DEFINITIONS OF KEY FINANCIAL FIGURES


 Operating profit before             = Operating profit + depreciation
 depreciation (EBITDA)



 Return on equity (ROE), %           = Profit/loss for the period x 100/
                                      -----------------------------------------
                                       Equity(Average for the period)



 Return on investment (ROI), %       = (Profit/loss before tax + interest and
                                       other financial expenses) x 100/
                                      -----------------------------------------
                                       Balance sheet total - non-interest
                                       bearing liabilities(average for the
                                       period)



 Equity ratio, %                     = Equity x 100/
                                      -----------------------------------------
                                       Balance sheet total - advances received



 Net interest-bearing liabilities    = Interest-bearing liabilities - cash and
                                       cash equivalents



 Net gearing ratio, %                = (Interest-bearing liabilities - cash and
                                       cash equivalents) x 100/
                                      -----------------------------------------
                                       Equity



 Earnings per share                  = Profit/loss for the period attributable
                                       to  equity holders of the parent
                                       company/
                                      -----------------------------------------
                                       Adjusted weighted average number of
                                       shares in issue during the period



 Equity per share                    = Equity attributable to equity holders of
                                       the parent company/
                                      -----------------------------------------
                                       Adjusted number of shares at the end of
                                       the period



 Dividend per share                  = Dividend for the period/
                                      -----------------------------------------
                                       Adjusted number of shares at the end of
                                       the period



 Effective dividend yield, %         = Dividend per share x 100/
                                      -----------------------------------------
                                       Trading price at the end of the period



 Price/earnings ratio (P/E)          = Last adjusted trading price at the end
                                       of the period/
                                      -----------------------------------------
                                       Earnings per share



 Average trading price               = Total traded amount in euro/
                                      -----------------------------------------
                                       Adjusted number of shares traded during
                                       the period



 Market capitalisation at the end of = Number of shares at the end of the
 the period                            period x trading price at the end of the
                                       period



 Trading volume                      = Number of shares traded during the
                                       period/
                                      -----------------------------------------
                                       Weighted average number of shares during
                                       the period


All figures of the financial tables are rounded, and consequently the sum of
individual figures can deviate from the presented sum figure.

The future estimates and forecasts in this interim report are based on the
company management's current knowledge. Actual events and results may differ
from the estimates presented here.


INTERIM REPORT BRIEFING

A briefing for investors, analysts and media will take place at Bank Meeting
Point, Unioninkatu 20, Helsinki (2nd floor) today Thursday, 23 October 2014 at
8.30 a.m. The result will be presented by President Kai Seikku. Welcome!


OKMETIC OYJ

Board of directors

For further information, please contact:

President Kai Seikku, Okmetic Oyj,
tel. +358 5028 0232, email: kai.seikku@okmetic.com

Senior Vice President, Finance, IT and Communications
Juha Jaatinen, Okmetic Oyj, tel. +358 9 5028 0286,
email: juha.jaatinen@okmetic.com

Distribution:
Nasdaq Helsinki
Principal media
www.okmetic.com

OKMETIC IN BRIEF

Okmetic is a technology company which supplies tailor-made silicon wafers for
sensor and semiconductor industries and sells its technological expertise.
Okmetic provides its customers with solutions that boost their competitiveness
and profitability.

Okmetic's silicon wafers are part of a further processing chain that produces
end products that improve human interaction and quality of life. Okmetic's
products are based on high-tech expertise that generates added value for
customers, innovative product development and an extremely efficient production
process.

Okmetic has a global customer base and sales network, production plants in
Finland and the US and contract manufacturers in Japan and China. Okmetic's
shares are listed on Nasdaq Helsinki under the code OKM1V. For more information
on the company, please visit our website at www.okmetic.com.


[HUG#1864809]

Attachments

Okmetic interim report Q3 2014.pdf